PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED

单独/联合使用氢脲的 I/II 期给药安全性和抗病毒活性

• 批准号: 6219898
• 负责人: GILDON N BEALL
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219898
• 关键词: 2'3' dideoxyinosine; AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; clinical research; clinical trial phase I; combination chemotherapy; dosage; drug screening /evaluation; gastrointestinal drug absorption; human immunodeficiency virus; human subject; human therapy evaluation; hydroxyurea; outcomes research; virus load

To test the safety of two doses of a drug, hydroxyurea, given alone or together with another drug, DDI, in persons infected with the HIV. This study also will see if hydroxyurea given alone or together with DDI decreases the amount of virus in the blood of HIV-infected persons as compared to DDI given alone. In addition, how DDI and hydroxyurea are absorbed into the body will also be looked at. Hydroxyurea has been used in a large number of sickle cell patients, but its use in HIV-infected persons is new and has been limited

在HIV感染者中检测两种剂量的药物（羟基脲）单独或与另一种药物（DDI）联合给药的安全性。 这项研究还将观察与单独给予DDI相比，单独给予或与DDI一起给予羟基脲是否会减少HIV感染者血液中的病毒量。 此外，还将研究DDI和羟基脲如何被吸收到体内。 羟基脲已用于大量镰状细胞病患者，但其用于艾滋病毒感染者是新的，一直受到限制